Centessa to Advance Orexin Agent ORX750 to Phase 2 Studies Following Positive Interim Data

Published Date: 19 Sep 2024

In the phase 1 trial, the 2.5 mg dose of ORX750 significantly improved wakefulness, restoring normal sleep latency to 32 minutes compared to placebo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radioactive ion beams successfully treat animal tumors in study

2.

A computer-aided diagnostic system for improved detection of breast cancer.

3.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

4.

Study reveals that older women frequently receive an incorrect breast cancer diagnosis.

5.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot